Understanding neuronal pathways: novel targets for the management of insomnia.

From the Sleep Disorders and Research Center, Henry Ford Hospital, Detroit, Mich. The symposium “Understanding Neuronal Pathways: Novel Targets for the Management of Insomnia,” a satellite symposium of SLEEP 2006, the 20th Anniversary Meeting of the Associated Professional Sleep Societies (APSS), was held June 19, 2006, in Salt Lake City, Utah, and supported by an educational grant from Merck and Lundbeck. Dr. Roth is a consultant for Abbott, Acadia, Acoglix, Actelion, Alchemers, Alza, Ancil, Arena, AstraZeneca, Aventis, Bristol-Myers Squibb, Cephalon, Cypress, Dove, Elan, Eli Lilly, Evotec, Forest, GlaxoSmithKline, Hypnion, Jazz, Johnson & Johnson, King, Lundbeck, McNeil, MediciNova, Merck, Neurim, Neurocrine, Neurogen, Novartis, Orexo, Organon, Orginer, Prestwick, Proctor and Gamble, Pfizer, Purdue, Resteva, Roche, Sanofi, ScheringPlough, Sepracor, Servier, Shire, Somaxon, Syrex, Takeda, TransOral, Vanda, Vivometrics, Wyeth, Yamanuchi, and Xenoport; has received grant/research support from Aventis, Cephalon, GlaxoSmithKline, Neurocrine, Pfizer, Sanofi, Schering-Plough, Sepracor, Somaxon, Syrex, Takeda, TransOral, Wyeth, and Xenoport; and is a member of the speakers/advisory boards for Sanofi and Takeda. Corresponding author and reprints: Thomas Roth, Ph.D., Sleep Disorders and Research Center, Henry Ford Hospital, 2799 West Grand Blvd., Detroit, MI 48202 (e-mail: [email protected]). Introduction